Neuberger Berman Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Neuberger Berman Group’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,578	Closed	-$375K	–	1940
2022 Q2	$375K	Buy	2,578 +619	+32%	+$79.1K	﹤0.01%	1570
2022 Q1	$232K	Buy	1,959 +25	+1%	+$3.12K	﹤0.01%	1769
2021 Q4	$241K	Buy	+1,934	New	+$246K	﹤0.01%	1783
2021 Q1	–	Sell	-22,045	Closed	-$1.89M	–	1872
2020 Q4	$1.89M	Buy	+22,045	New	+$1.87M	﹤0.01%	1123
2020 Q1	–	Sell	-22,500	Closed	-$1.23M	–	1674
2019 Q4	$1.23M	Sell	22,500 -17,500	-44%	-$867K	﹤0.01%	1123
2019 Q3	$1.67M	Sell	40,000 -7,500	-16%	-$317K	﹤0.01%	1050
2019 Q2	$2.08M	Buy	47,500 +22,000	+86%	+$1.24M	﹤0.01%	1024
2019 Q1	$1.31M	Buy	25,500 +15,500	+155%	+$670K	﹤0.01%	1060
2018 Q4	$370K	Buy	+10,000	New	+$361K	﹤0.01%	1319

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Neuberger Berman Group's BHVN Position: Q3 2022 in Review

Neuberger Berman Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 2,578 shares — an estimated $375K sold.

Neuberger Berman Group first reported a position in BHVN in Q4 2018 and held it in 9 quarters. The position peaked at $2.08M in Q2 2019. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Neuberger Berman Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Neuberger Berman Group sold 2,578 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $375K.
Neuberger Berman Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 9 quarters.
Neuberger Berman Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.08M in Q2 2019.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Neuberger Berman Group's 13F filing for Q3 2022, filed 15 Nov 2022.